237 related articles for article (PubMed ID: 26190501)
1. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
[TBL] [Abstract][Full Text] [Related]
2. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852
[TBL] [Abstract][Full Text] [Related]
3. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
[TBL] [Abstract][Full Text] [Related]
4. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
5. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
Sawada Y; Kawaratani H; Kubo T; Fujinaga Y; Furukawa M; Saikawa S; Sato S; Seki K; Takaya H; Okura Y; Kaji K; Shimozato N; Mashitani T; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yamao J; Yoshiji H
Hepatol Res; 2019 Mar; 49(3):284-295. PubMed ID: 30365236
[TBL] [Abstract][Full Text] [Related]
6. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.
Namisaki T; Moriya K; Kitade M; Takeda K; Kaji K; Okura Y; Shimozato N; Sato S; Nishimura N; Seki K; Kawaratani H; Takaya H; Sawada Y; Akahane T; Saikawa S; Nakanishi K; Kubo T; Furukawa M; Noguchi R; Asada K; Kitagawa K; Ozutsumi T; Tsuji Y; Kaya D; Fujinaga Y; Yoshiji H
Hepatol Commun; 2017 Nov; 1(9):928-945. PubMed ID: 29404501
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
8. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
Douhara A; Moriya K; Yoshiji H; Noguchi R; Namisaki T; Kitade M; Kaji K; Aihara Y; Nishimura N; Takeda K; Okura Y; Kawaratani H; Fukui H
Mol Med Rep; 2015 Mar; 11(3):1693-700. PubMed ID: 25421042
[TBL] [Abstract][Full Text] [Related]
9. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
Shimozato N; Namisaki T; Kaji K; Kitade M; Okura Y; Sato S; Moriya K; Seki K; Kawaratani H; Takaya H; Sawada Y; Saikawa S; Nakanishi K; Furukawa M; Fujinaga Y; Kubo T; Asada K; Kitagawa K; Tsuji Y; Kaya D; Ozutsumi T; Akahane T; Mitoro A; Yoshiji H
Hepatol Res; 2019 Oct; 49(10):1147-1161. PubMed ID: 31177586
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
12. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
Nakanishi K; Kaji K; Kitade M; Kubo T; Furukawa M; Saikawa S; Shimozato N; Sato S; Seki K; Kawaratani H; Moriya K; Namisaki T; Yoshiji H
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163617
[TBL] [Abstract][Full Text] [Related]
13. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
Tamaki Y; Nakade Y; Yamauchi T; Makino Y; Yokohama S; Okada M; Aso K; Kanamori H; Ohashi T; Sato K; Nakao H; Haneda M; Yoneda M
J Gastroenterol; 2013 Apr; 48(4):491-503. PubMed ID: 22886508
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.
Pathil A; Mueller J; Ludwig JM; Wang J; Warth A; Chamulitrat W; Stremmel W
Br J Pharmacol; 2014 Nov; 171(22):5113-26. PubMed ID: 25041068
[TBL] [Abstract][Full Text] [Related]
17. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
[TBL] [Abstract][Full Text] [Related]
18. Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development.
Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Shirai Y; Yoshii J; Yanase K; Fukui H
Int J Mol Med; 2011 Jul; 28(1):81-8. PubMed ID: 21455560
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
20. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
